Edition:
United Kingdom

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

29.92USD
9:00pm BST
Change (% chg)

$-0.04 (-0.13%)
Prev Close
$29.96
Open
$30.01
Day's High
$30.10
Day's Low
$29.52
Volume
186,575
Avg. Vol
131,158
52-wk High
$30.24
52-wk Low
$11.45

Latest Key Developments (Source: Significant Developments)

Apellis Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.APELLIS PHARMACEUTICALS INC - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $75 MILLION OF SHARES OF ITS COMMON STOCK.  Full Article

Apellis Pharmaceuticals' APL-2 Receives Fast Track Designation From The FDA
Monday, 11 Feb 2019 

Feb 11 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS’ APL-2 RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR THE TREATMENT OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.APELLIS PHARMACEUTICALS - NEW FAST TRACK DESIGNATION FOR APL-2 FOR ALL PATIENTS WITH PNH, SUPERSEDES PRIOR FAST TRACK DESIGNATION FROM ON DEC 15, 2016.  Full Article

Apellis Pharmaceuticals' Apl-2 Receives Orphan Drug Designation From FDA
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS’ APL-2 RECEIVES ORPHAN DRUG DESIGNATION FROM THE FDA FOR THE TREATMENT OF C3 GLOMERULOPATHY.APELLIS PHARMACEUTICALS INC - ITS C3 COMPLEMENT INHIBITOR, APL-2, HAS BEEN GRANTED ORPHAN DRUG DESIGNATION BY FDA.  Full Article

Apellis Pharmaceuticals Provides Update On Its Phase 3 Program For Patients With Geographic Atrophy
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS PROVIDES UPDATE ON ITS PHASE 3 PROGRAM FOR PATIENTS WITH GEOGRAPHIC ATROPHY.APELLIS PHARMACEUTICALS - PHASE 3 GEOGRAPHIC ATROPHY PROGRAM ENROLLMENT TIMELINE CURRENTLY UNCHANGED.APELLIS PHARMACEUTICALS INC - PROGRAM ENROLLMENT IS EXPECTED TO RESTART IN Q2 2019 AND ENROLLMENT COMPLETION IS EXPECTED IN Q1 2020.APELLIS PHARMACEUTICALS - TO RESUME PHASE 3 GA PROGRAM CO INTRODUCED IMPROVEMENTS TO MANUFACTURING PROCESS TO ELIMINATE IMPURITIES & POTENTIAL CONTAMINANTS.  Full Article

Apellis Pharmaceuticals Reports Q2 Loss Per Share Of $0.61
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS REPORTS SECOND QUARTER 2018 BUSINESS UPDATE AND FINANCIAL RESULTS.APELLIS PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.61.APELLIS PHARMACEUTICALS INC - PHASE 3 PROGRAM CONSISTING OF 2 TRIALS OF APL-2 IN GEOGRAPHIC ATROPHY REMAINS ON TRACK TO BEGIN IN H2 2018.APELLIS PHARMACEUTICALS INC - AS OF JUNE 30, 2018, APELLIS HAD $253.8 MILLION IN CASH & CASH EQUIVALENTS VERSUS $152.9 MILLION AS OF MARCH 31, 2018.  Full Article

Apellis Pharma's APL-2 Receives Fast Track Designation From FDA
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS’ APL-2 RECEIVES FAST TRACK DESIGNATION FROM FDA FOR THE TREATMENT OF PATIENTS WITH GEOGRAPHIC ATROPHY.APELLIS PHARMACEUTICALS - APELLIS PLANS TO INITIATE A PHASE 3 TRIAL FOR PATIENTS WITH GA LATER IN 2018.  Full Article

Apellis Pharma Provides Update On Two Phase Ib Trials For Patients With PNH
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS PROVIDES UPDATE ON TWO PHASE IB TRIALS FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).APELLIS - SEVERELY ANEMIC PATIENTS WITH PNH ON TREATMENT WITH SOLIRIS CAN BECOME TRANSFUSION-FREE WHEN SWITCHED TO APL-2 MONOTHERAPY.APELLIS - TREATMENT-NAÏVE PATIENTS WITH PNH SHOW CLINICALLY MEANINGFUL IMPROVEMENTS FOR ALL HEMATOLOGICAL PARAMETERS WHEN TREATED WITH APL-2.APELLIS - SUBCUTANEOUS APL-2 HAS GENERALLY BEEN WELL-TOLERATED WITH CUMULATIVE SYSTEMIC EXPOSURE OF OVER 12 PATIENT YEARS OF TREATMENT ON APL-2.  Full Article

Apellis Pharmaceuticals Announces Pricing Of Offering Of Common Stock
Thursday, 19 Apr 2018 

April 18 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS ANNOUNCES PRICING OF OFFERING OF COMMON STOCK.APELLIS PHARMACEUTICALS- PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 5.5 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $25.50 PER SHARE.  Full Article

Apellis Pharmaceuticals Provides Update On Phase 1B Open Label Study Of APL-2 In Pnh Patients Not Previously Treated With Eculizumab
Monday, 16 Apr 2018 

April 16 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS PROVIDES UPDATE ON PHASE 1B OPEN LABEL STUDY OF APL-2 IN PNH PATIENTS NOT PREVIOUSLY TREATED WITH ECULIZUMAB.APELLIS PHARMACEUTICALS INC - TO DATE, APL-2 HAS GENERALLY BEEN WELL-TOLERATED IN PATIENTS.APELLIS PHARMACEUTICALS INC - EXPECTS TO REPORTING FURTHER UPDATES TO ONGOING PADDOCK TRIAL IN JUNE.APELLIS - IN H2 2018, PLANS TO INITIATE A PHASE 3 TRIAL IN 70 PATIENTS WITH PNH VERSUS TREATMENT WITH APL-2 MONOTHERAPY TO TREATMENT WITH ECULIZUMAB.  Full Article

Apellis Finalizes Late Stage Trial Plans For Eye Disease Treatment
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS FINALIZES PHASE 3 CLINICAL TRIAL PLANS FOR GEOGRAPHIC ATROPHY TREATMENT WITH APL-2.APELLIS PHARMACEUTICALS INC - PHASE 3 PROGRAM EVALUATING APL-2 PLANNED TO BEGIN IN SECOND HALF OF 2018.APELLIS PHARMACEUTICALS - PHASE 3 PROGRAM TO CONSIST OF TWO IDENTICAL 600-PATIENT STUDIES TO ASSESS EFFICACY,SAFETY.APELLIS PHARMACEUTICALS INC - PHASE 3 TRIALS EVALUATING APL-2 WILL BE SUBSTANTIALLY SIMILAR IN DESIGN TO APELLIS' ONGOING PHASE 2 FILLY TRIAL.  Full Article